Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Open-label Study to Evaluate the Safety and Tolerability of KD025 [Belumosudil] Treatment in Subjects With Moderately Severe Psoriasis Vulgaris Who Have Failed First-line Therapy

NCT02106195 is registered in ClinicalTrials.gov with Kadmon Corporation, LLC as lead sponsor.

NCT NCT02106195
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02106195 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Open-label Study to Evaluate the Safety and Tolerability of KD025 [Belumosudil] Treatment in Subjects With Moderately Severe Psoriasis Vulgaris Who Have Failed First-line Therapy
Lead sponsor
Kadmon Corporation, LLC
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2014
Completion date
September 30, 2014
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis vulgaris